Mar 15, 2019 7:00am EDT Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
Mar 05, 2019 7:00am EST Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference
Jan 29, 2019 7:00am EST Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Nov 13, 2018 7:00am EST Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer
Oct 12, 2018 7:00am EDT Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma
